Home example 2 - Pharmamarketeer

wet- en regelgeving

Merck gets CHMP positive opinion for Rebif label amendment during pregnancy as clinically needed and while breastfeeding

Merck, a leading science and technology company, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion to update

Pharma Biz

6 x gelezen

technologie

A new deep learning approach to predict disease-associated mutations

Disease-associated mutations
During the past years, artificial intelligence (AI) — the capability of a machine to mimic human behavior — has become a key player in high-techs like drug development projects.

News-Medical.Net

6 x gelezen

overig

Steeds meer audio geconsumeerd

Er wordt steeds meer audio geconsumeerd, het aantal streaming uren in januari 2022 is 10 procent gestegen naar 32,8 miljoen streaming uren per week, zo blijkt uit het Audiojaarrapport 2021 van branchevereniging Audify...

Emerce

6 x gelezen

onderzoek

Roche’s Tecentriq cocktail boosts survival in small cell lung cancer

Swiss drugmaker Roche said on Monday that a cocktail of its immunotherapy Tecentriq with chemotherapy boosted survival of patients with previously untreated extensive-stage small cell lung cancer compared with...

Reuters Health

6 x gelezen

wet- en regelgeving

Upadacitinib Gets FDA’s Priority Review for Treatment of Moderate to Severe RA

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for upadacitinib (AbbVie), an investigational oral JAK1-selective inhibitor, for the treatment of moderate to severe...

Monthly Prescribing Reference (MPR): Drugs in the Pipeline

6 x gelezen

wet- en regelgeving

FDA approves first paediatric treatment for intra-abdominal and urinary tract infections in over 10 years

Allergan has revealed that Avycaz (ceftazidime and avibactam) has been awarded an expansion of its label by the FDA to include the treatment of complicated intra-abdominal infections (cIAI) in combination with...

InPharm.com

6 x gelezen

onderzoek

Invokana® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study

Invokana® (canagliflozin) is the only medicine in nearly 20 years and the first diabetes medicine to demonstrate significant reduction in risk of renal failure, dialysis or kidney transplantation and renal or...

Drug Discovery Today: Technologies

6 x gelezen

farma-industrie onderzoek

Novartis provides promising update on Cosentyx in plaque psoriasis

Novartis has revealed brief new data on its IL-17A antibody Cosentyx (secukinumab) in the treatment off plaque psoriasis, showing that the therapy “improves inflammation and rapidly supresses IL-23” in cases of the...

InPharm.com

6 x gelezen

marketing

Productpagina’s in 2020: 5 voorspellingen

Productpagina’s in 2020 December is niet alleen de feestelijke maand waarin we sinterklaas, kerst en nieuwjaar vieren, maar ook de maand waarin de nieuwe marketingbudgetten worden bepaald en de plannen voor het komende...

Frankwatching.nl

6 x gelezen

onderzoek

Roche’s Xofluza proves non-inferior to Tamiflu in children with flu

Roche has unveiled new Phase 3 data indicating that Xofluza (baloxavir marboxil) was well-tolerated and of comparable efficacy to its other therapy Tamiflu (oseltamivir) in the reduction of the duration of the symptoms...

InPharm.com

6 x gelezen

Latest articles

Merck gets CHMP positive opinion for Rebif label amendment during pregnancy as clinically needed and while breastfeeding

A new deep learning approach to predict disease-associated mutations

Steeds meer audio geconsumeerd

Roche’s Tecentriq cocktail boosts survival in small cell lung cancer

Upadacitinib Gets FDA’s Priority Review for Treatment of Moderate to Severe RA

FDA approves first paediatric treatment for intra-abdominal and urinary tract infections in over 10 years

Invokana® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study

Novartis provides promising update on Cosentyx in plaque psoriasis

Productpagina’s in 2020: 5 voorspellingen

Roche’s Xofluza proves non-inferior to Tamiflu in children with flu

Wekelijkse highlights per e-mail

Algemene informatie